Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kari J. Kurppa, Yao Liu, Ciric To, +41

Cancer Cell

Tumor BiologySignaling PathwayCell RegulationMedicineTreatment-induced Tumor Dormancy +8

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi, +29

Journal of Thoracic Oncology

Tumor BiologyProgrammed Death-MedicineCell DeathBronchial Neoplasm +8

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Navin R. Mahadevan, Erik H. Knelson, Jacquelyn O. Wolff, +39

Cancer Discovery

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Kartik Sehgal, Andrew Portell, Elena V. Ivanova, +25

Journal of Clinical Investigation

Cell TherapyPd-1 BlockadeImmunologyImmune RegulationImmunoediting +22

Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment

Péter M. Szabó, Amir Vajdi, Namit Kumar, +16

Scientific Reports

Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer

Deli Hong, Erik H. Knelson, Yixiang Li, +16

Cancer Research

Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1

Hsiao-Yun Chen, Yavuz T. Durmaz, Yixiang Li, +14

Nature Communications

Molecular RegulationGeneticsEpigeneticsRna-binding Protein Zfp36l1Lsd1 Target Gene +14

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Ryohei Yoshida, Maria Saigí, Tetsuo Tani, +21

Cancer Research

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.

Charles M. Rudin, Hye Ryun Kim, Alejandro Navarro, +17

Journal of Clinical Oncology

Keynote-604 StudyImmunologyPathologyTumor BiologyExtensive-stage Sclc +24

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, +21

Nature Medicine